Shooting for the Moon or Flying Too Near the Sun? Crossing the Value Rubicon in Precision Cancer Care

Public Health Genomics

Volumn 19, Issue 3, 2016, Pages 132-136

  Lawler, Mark ^a   French, Declan ^b   Henderson, Raymond ^a,b   Aggarwal, Ajay ^c   Sullivan, Richard ^c  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer care; Costs of cancer care; Personalised and precision medicine

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB; ANTINEOPLASTIC AGENT;

ACCURACY; ARTICLE; BUDGET; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; CHILDHOOD CANCER; CHRONIC MYELOID LEUKEMIA; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PUBLIC HEALTH; HEALTH CARE DELIVERY; MOTIVATION; NEOPLASMS;

ANTINEOPLASTIC AGENTS; DELIVERY OF HEALTH CARE; GOALS; HUMANS; NEOPLASMS; PRECISION MEDICINE;

EID: 84977103148     PISSN: 16624246     EISSN: 16628063     Source Type: Journal    
DOI: 10.1159/000446530     Document Type: Article

References (40)

1. Kaiser J, Couzin-Frankel J: Biomedical research. Biden seeks clear course for his cancer moonshot. Science 2016; 351: 325-326.
2. Goldman JM, Druker BJ: Chronic myeloid leukemia: current treatment options. Blood 2001; 98: 2039-2042.
3. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-1056.
4. Verweij J, Casali PG, Zalcberg J, et al: Progression- free survival in gastrointestinal stromal tumors with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127-1134.
5. Tasian SK, Loh ML, Hunger SP: Childhood acute lymphoblastic leukemia: integrating genomics into therapy. Cancer 2015; 121: 3577-3590.
6. Irwin MS, Park JR: Neuroblastoma: paradigm for precision medicine. Pediatr Clin North Am 2015; 62: 225-256.
7. Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368: 2385-2394.
8. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
9. Katayama R, Lovly CM, Shaw AT: Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res 2015; 21: 2227-2235.
10. Doroshow JH, Kummar S: Translational research in oncology - 10 years of progress and future prospects. Nat Rev Clin Oncol 2014; 11: 649-662.
11. Kirk R: Risk factors. Oncotype DX assay predicts local recurrence in breast cancer. Nat Rev Clin Oncol 2010; 7: 300.
12. Eggermont A, Robert C, Soria JC, Zitvogel L: Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors. Oncoimmunology 2014; 3:e27560.
13. Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, Narwal R, Steele K, Gu Y, Karakunnel JJ, Rizvi NA: Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol 2016; 17: 299-308.
14. Melosky B, Chu Q, Juergens R, Leighl N, McLeod D, Hirsh V: Pointed progress in second- line advanced non-small-cell lung cancer: the rapidly evolving field of checkpoint inhibition. J Clin Oncol 2016; 34: 1676-1688.
15. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A: Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16: 908-918.
16. Postel-Vinay S, Aspeslagh S, Lanoy E, Robert C, Soria JC, Marabelle A: Challenges of phase 1 clinical trials evaluating immune checkpoint- targeted antibodies. Ann Oncol 2016; 27: 214-224.
17. Ilie M, Hofman V, Dietel M, Soria JC, Hofman P: Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch 2016; 468: 511-525.
18. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-1403.
19. Meara JG, Leather AJ, Hagander L, et al: Global Surgery 2030: evidence and solutions for achieving health, welfare, and economic development. Lancet 2015; 386: 569-624.
20. Hoskin P, Sartor O, O'Sullivan JM, Johannessen DC, Helle SI, Logue J, Bottomley D, Nilsson S, Vogelzang NJ, Fang F, Wahba M, Aksnes AK, Parker C: Efficacy and safety of radium-223 dichloride in patients with castration- resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 2014; 15: 1397-1406.
21. Reiners C, Dietlein M, Luster M: Radio-iodine therapy in differentiated thyroid cancer: indications and procedures. Best Pract Res Clin Endocrinol Metab 2008; 22: 989-1007.
22. Koh PK, Faivre-Finn C, Blackhall FH, De Ruysscher D: Targeted agents in non-small cell lung cancer (NSCLC): clinical developments and rationale for the combination with thoracic radiotherapy. Cancer Treat Rev 2012; 38: 626-640.
23. Chalmers AJ, Lakshman M, Chan N, Bristow RG: Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Semin Radiat Oncol 2010; 20: 274-281.
24. Lawler M, Kaplan R, Wilson RH, Maughan T; S-CORT Consortium: Changing the paradigm- multistage multiarm randomized trials and stratified cancer medicine. Oncologist 2015; 20: 849-851.
25. Lawler M, Selby P: Personalized cancer medicine: are we there yet? Oncologist 2013; 18: 649-650.
26. Gambacorti-Passerini C, Piazza R: Imatinib - a new tyrosine kinase inhibitor for first-line treatment of chronic myeloid leukemia in 2015. JAMA Oncol 2015; 1: 143-144.
27. Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, Abruzzese E, Martino B, Levato L, Intermesoli T, Pregno P, Rossi G, Gherlinzoni F, Leoni P, Cavazzini F, Venturi C, Soverini S, Testoni N, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party: Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia 2015; 29: 1823-1831.
28. Red Book online database. http://www.redbook.com (accessed March 1, 2016).
29. Experts in Chronic Myeloid Leukemia: The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013; 121: 4439-4442.
30. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
31. Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EG, Piccart MJ: A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015; 26: 1547-1573.
32. Conti RM, Padula WV, Larson RA: Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU. Ann Hematol 2015; 94:S249-S257.
33. Vogler S, Vitry A, Babar ZU: Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. Lancet Oncol 2016; 17: 39-47.
34. van Harten WH, Wind A, de Paoli P, Saghatchian M, Oberst S: Actual costs of cancer drugs in 15 European countries. Lancet Oncol 2016; 17: 18-20.
35. Fojo T, Lo AW: Price, value, and the cost of cancer drugs. Lancet Oncol 2016; 17: 3-5.
36. Mailankody S, Prasad V: Five years of cancer drug approvals: innovation, efficacy, and costs. JAMA Oncol 2015; 1: 539-540.
37. Lawler M, Le Chevalier T, Banks I, Conte P, De Lorenzo F, Meunier F, Pinedo HM, Selby P, Murphy MJ, Johnston PG; European Cancer Concord (ECC): A bill of rights for patients with cancer in Europe. Lancet Oncol 2014; 15: 258-260.
38. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA: Cancer drugs in the United States: Justum Pretium - the just price. J Clin Oncol 2013; 31: 3600-3604.
39. Sullivan R, Aggarwal A: Health policy: putting a price on cancer. Nat Rev Clin Oncol 2016; 13: 137-138.
40. World Health Organisation Regional Office for Europe: European Health Report 2012: Charting the Way to Well-Being. Copenhagen, World Health Organisation Regional Office for Europe, 2013.